For the year ending 2025-12-31, KALV has $335,375K in assets. $338,086K in debts. $229,342K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 229,342 | |||
| Marketable securities | 70,872 | |||
| Accounts receivable, net | 2,593 | |||
| Inventory | 3,428 | |||
| Research and development tax credit receivable | 6,200 | |||
| Prepaid expenses and other current assets | 7,712 | |||
| Total current assets | 320,147 | |||
| Property and equipment, net | 3,034 | |||
| Right of use assets | 9,825 | |||
| Other assets | 2,369 | |||
| Total assets | 335,375 | |||
| Accounts payable | 8,268 | |||
| Accrued expenses and other current liabilities | 33,897 | |||
| Lease liability - current portion | 1,621 | |||
| Royalty obligation - current portion | 13,569 | |||
| Total current liabilities | 57,355 | |||
| Deferred revenue - net of current portion | 11,714 | |||
| Lease liability - net of current portion | 10,727 | |||
| Royalty obligation - net of current portion | 119,063 | |||
| Convertible notes | 139,227 | |||
| Total liabilities | 338,086 | |||
| Common stock, 0.001 par value 100,000,000 shares authorized at december 31, 2025, april 30, 2025 and april 30, 2024 50,900,777, 49,762,048 and 42,521,975 shares issued and outstanding at december 31, 2025, april 30, 2025 and april 30, 2024, respectively | 51 | |||
| Additional paid-in capital | 767,061 | |||
| Accumulated deficit | -762,694 | |||
| Accumulated other comprehensive loss | -7,129 | |||
| Total stockholders' (deficit) equity | -2,711 | |||
| Total liabilities and stockholders' (deficit) equity | 335,375 | |||
KalVista Pharmaceuticals, Inc. (KALV)
KalVista Pharmaceuticals, Inc. (KALV)